The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Novel Statistical Tools for Monitoring the Safety of Marketed Drugs
Abstract
Robust tools for monitoring the safety of marketed therapeutic products are of paramount importance to public health. In recent years, innovative statistical approaches have been developed to screen large post-marketing safety databases for adverse events (AEs) that occur with disproportionate frequency. These methods, known variously as quantitative signal detection, disproportionality analysis, or safety data mining, facilitate the identification of new safety issues or possible harmful effects of a product. In this article, we describe the statistical concepts behind these methods, as well as their practical application to monitoring the safety of pharmaceutical products using spontaneous AE reports. We also provide examples of how these tools can be used to identify novel drug interactions and demographic risk factors for adverse drug reactions. Challenges, controversies, and frontiers for future research are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Elements of Statistical Learning
Hastie, T., Friedman, J., & Tibshirani, R. (2001) · Springer Series in Statistics · doi:10.1007/978-0-387-21606-5 · Cited by 24,162
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
Self-citationWacholder, S., Chanock, S., Garcia-Closas, M., El ghormli, L., & Rothman, N. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh075 · Cited by 1,754
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476
van Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, A. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,372
Dumouchel, W. (1999) · The American Statistician · doi:10.1080/00031305.1999.10474456 · Cited by 878
Self-citationSzarfman, A., Machado, S. G., & O??Neill, R. T. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 700
Cited by
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
Slade, B. A. (2009) · JAMA · doi:10.1001/jama.2009.1201 · Cited by 470
Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.50 · Cited by 393
Self-citationSGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Fadini, G. P., Bonora, B. M., & Avogaro, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4301-8 · Cited by 242
Gender differences in adverse event reports associated with antidiabetic drugs
Joung, K.-I., Jung, G.-W., Park, H.-H., Lee, H., Park, S.-H., & Shin, J.-Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-74000-4 · Cited by 61
Metadata
- Authors
- Almenoff, J. S., Pattishall, E. N., Gibbs, T. G., DuMouchel, W., Evans, S. J. W., & Yuen, N.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-05-30
- Volume
- 82
- Issue
- 2
- Pages
- 157-166
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1996239270
- Cited by
- 266
- References
- 46
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Statistical Tools for Monitoring the Safety of Marketed Drugs. https://app.cochat.ai/papers/10.1038/sj.clpt.6100258
- The paper
- Almenoff, J. S., Pattishall, E. N., Gibbs, T. G., DuMouchel, W., Evans, S. J. W., & Yuen, N. (2007). Novel Statistical Tools for Monitoring the Safety of Marketed Drugs. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/sj.clpt.6100258
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.